Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease

Trial ID or NCT#

NCT00186667

Status

not recruiting iconNOT RECRUITING

Purpose

Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.

Official Title

An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant

Eligibility Criteria

Ages Eligible for Study: 18 Years to 70 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - active chronic GvHD - ANC > 1000/mm^3 - therapeutic cyclosporine
Exclusion Criteria:
  1. - uncontrolled systemic infection - elevated serum creatinine
View All Criteria
Show Less

Investigator(s)

Laura Johnston
Laura Johnston
Blood and marrow transplant specialist, Blood and marrow transplant specialist, Medical oncologist, Hematologist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Contact us to find out if this trial is right for you.

Contact

BMT Referrals
6507230822

View on ClinicalTrials.gov